Last reviewed · How we verify

Feraheme — Competitive Intelligence Brief

Feraheme (FERUMOXYTOL) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Parenteral Iron Replacement [EPC]. Area: Hematology.

marketed Parenteral Iron Replacement [EPC] Hematology Live · refreshed every 30 min

Target snapshot

Feraheme (FERUMOXYTOL) — Covis. Feraheme delivers iron to macrophages where it is released and either stored or transported to erythroid precursor cells.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Feraheme TARGET FERUMOXYTOL Covis marketed Parenteral Iron Replacement [EPC] 2009-01-01
IRON SUCROSE IRON SUCROSE marketed Parenteral Iron Replacement [EPC] 2000-01-01
Sodium Ferric Gluconate Complex in Sucrose. Sodium Ferric Gluconate Complex in Sucrose. Watson Pharmaceuticals marketed Parenteral Iron Replacement [EPC]
SUCROSE SUCROSE marketed Parenteral Iron Replacement [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Parenteral Iron Replacement [EPC] class)

  1. · 2 drugs in this class
  2. Covis · 1 drug in this class
  3. Watson Pharmaceuticals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Feraheme — Competitive Intelligence Brief. https://druglandscape.com/ci/ferumoxytol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: